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Background: The histological pattern of pleuroparenchymal ﬁbroelastosis (PPFE) is well
deﬁned, but its clinical features remain unclear.
Methods: We retrospectively examined the predominantly involved lung-ﬁelds (based on
abnormal opacities on computed tomography [CT] images), and the initial value and annual
decline of respiratory function in patients with pulmonary ﬁbrosis presenting with histologically
conﬁrmed PPFE.
Results: Thirteen female and nine male subjects were included. Eleven interpreters indepen-
dently analyzed 231 CT image series. One-third of the CT series (78/231) was interpreted as
demonstrating equal involvement of the upper and lower lung ﬁelds, i.e., six out of 21 patients
had equal involvement of the upper and lower lung ﬁelds, based on a majority decision of the
interpreters. The residual volume/total lung capacity (RV/TLC) was increased and correlated
inversely with forced vital capacity (FVC) at the initial measurement. FVC followed two patterns
of decline over time: a gradual decline over a follow-up period of more than 6 years (55mL/
year, R2¼0.799), and a relatively rapid decline over a shorter period (364mL/year, R2¼0.855) as
determined by mixed-effect linear regression.
Conclusions: The predominantly involved sites seen on CT images of PPFE were not limited to the
upper lobes. In some cases, upper lung ﬁelds were predominantly involved, but in other cases,
both upper and lower lung ﬁelds were equally involved. Two patterns of FVC decline exists: a
rapid decline over a short period and a slow decline over a longer period, suggesting that the
disease follows a heterogeneous clinical course.
& 2015 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.Society. Published by Elsevier B.V. All rights reserved.
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In 2013, the American Thoracic Society (ATS) and the European
Respiratory Society (ERS) updated the international multidis-
ciplinary classiﬁcation of idiopathic interstitial pneumonias
(IIPs) [1]. According to this classiﬁcation, idiopathic pleuropar-
enchymal ﬁbroelastosis (PPFE) is one of the rare IIPs.
The concept of idiopathic PPFE overlaps with that of idio-
pathic pulmonary upper lobe-localized ﬁbrosis (IPUF) proposed
by Amitani (Amitani disease) [2] and that of pulmonary upper
lobe-dominant ﬁbrosis [3–5]. Currently, idiopathic PPFE is the
globally accepted nomenclature for these ﬁbroses with unknown
etiology. However, the worldwide accumulation of case series of
PPFE has led to evolution of this concept [6–15], although some
issues remain unclear. Despite the deﬁned nature of the histo-
logical pattern of PPFE, the clinical manifestation seems to be
heterogeneous. The histological pattern of PPFE is found with a
variety of conditions, such as repeated infections, autoimmune
diseases, a family history of interstitial pneumonias, asbestos
exposure, and in response to anticancer chemotherapeutic
agents, including cyclophosphamide [6,7,10,14,15], while
transplantation-associated PPFE was also reported recently
[9,12,13,16]. This complicates the assessment of PPFE pathogen-
esis. Although the PPFE imaging pattern is thought to represent
upper lobe ﬁbrosis [1], PPFE may be a more diffuse process that is
not limited to the upper lobes [14], and no convincing imaging
studies have been published showing upper lobe predominance.
This ﬁbrotic disease may progress irreversibly to end-stage
ﬁbrosis [1], but its prognosis is unclear. Amitani disease is a
slowly progressive ﬁbrosis with a presentation of 10–20 years [2].
PPFE is a “rare” pulmonary ﬁbrosis, and the number of
patients in the case-series studies reported in the past has
been fewer than 20. Here, we present the clinical, imaging,
and physiological characteristics of 22 patients with pulmon-
ary ﬁbrosis and histologically proven PPFE.2. Patients and methods
2.1. Patient selection
We reviewed the medical ﬁles of all patients who were
hospitalized in the Departments of Respiratory Medicine at
the Fukuoka University Hospital, Omuta National Hospital,
Fukuoka Higashi Medical Center, Hamanomachi Hospital, and
Kyushu University Hospital, from 2000 to 2014, and found 23
patients with pulmonary ﬁbrosis and histologically proven PPFE
who had undergone surgical lung biopsy (SLB) and/or autopsy.
We excluded a case of PPFE that occurred in transplanted lungsAbbreviations: BMI, body mass index; DLco, diffusing capacity of
vital capacity; HRCT, high-resolution computed tomography; IIP, id
ﬁbrosis; IPUF, idiopathic pulmonary upper lobe ﬁbrosis; NTM, non
ﬁbroelastosis; RV, residual volume; TLC, total lung capacity; UIP,
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yoshimimi@fukuokae2.hosp.go.jp (M. Yoshimi), hishii@fukuoka-u.ac.j
n-hamada@kokyu.med.kyushu-u.ac.jp (N. Hamada), mfujita@fukuoka
fumkiyomi@adm.fukuoka-u.ac.jp (F. Kiyomi), watanabe@fukuoka-u.ac
nCorresponding author. Tel.: þ81 92 801 1011; fax: þ81 92 865 6220.[16], because an estimation of the predominantly involved sites
was not possible in the transplanted lower lobes. After exclud-
ing this patient, 22 patients were eventually enrolled.2.2. Clinical data
We reviewed the patients' clinical records for age at onset, sex,
smoking status, steroid treatment, symptoms, crackles, and
body mass index (BMI). Comorbidities, past history (including
pneumothorax), and occupational history were also examined.
The follow-up interval from the onset of symptoms to the last
date of follow-up was determined, and information on the
prognosis of the patients was recorded.2.3. Histological and imaging ﬁndings
Histological specimens from SLB were obtained for 15
patients. Autopsy samples were obtained for four patients.
The remaining three patients who had undergone SLB under-
went left lung resection for lung transplantation and/or
autopsy at a later stage. Histological specimens, stained with
hematoxylin and eosin and with Elastica van Gieson, were
reviewed by KW, NN, and KN. PPFE was histologically diag-
nosed based on the following criteria: (1) increased elastic
ﬁbers with septal elastosis in the subpleural area, (2) intra-
alveolar collagen deposition associated with septal elastosis,
and (3) collagenous thickening of the visceral pleura. When
all three or the ﬁrst two criteria were met, a histological
pattern of PPFE was recognized [10,17].
Conventional or high-resolution computed tomography
(HRCT) images of the chest were reviewed for all but one
patient (it was unavailable for patient #7). We evaluated all of
the abnormal patterns identiﬁed in the lung parenchyma and
pleura, including nodules, consolidation, ground-glass opaci-
ties, reticulation, honeycombing, and cysts, seen on chest CT
images in the patients who presented with PPFE histology.
Such CT patterns were divided into three groups, based on the
primary involved site: upper lung ﬁeld predominance, lower
lung ﬁeld predominance, and equal involvement of upper and
lower lung ﬁelds. All authors, except for KN, interpreted all the
CT images of the 21 patients, independently. To decide on the
predominantly involved sites, the 11 interpreters read the ﬁrst
series of CT images available for each patient, totaling 231
series (11 interpreters21 patients). If consensus could not be
reached, the involved sites were decided based on majority
decision. An extended kappa value was calculated for the level
of agreement between the 11 interpreters.carbon monoxide; FRC, functional reserve capacity; FVC, forced
iopathic interstitial pneumonia; IPF, idiopathic pulmonary
tuberculous mycobacteria; PPFE, pleuroparenchymal
usual interstitial pneumonia
agata@fukuoka-u.ac.jp (N. Nagata),
(Y. Kitasato), wakamatsu-k@oomuta-h.com (K. Wakamatsu),
p (H. Ishii), tahirota@fukuoka-u.ac.jp (T. Hirota),
-u.ac.jp (M. Fujita), kaznabes@fukuoka-u.ac.jp (K. Nabeshima),
.jp (K. Watanabe).
Table 1 – Clinical characteristics.
Number of subjects 22
Age at onset: years 56.6711.0a
Sex: males/females 9/13
Smoking status: never-smokers/current or former
smokers
16/6
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Forced vital capacity (FVC) was measured using spirometry.
The results of this analysis are expressed as absolute values
(mL) and as percentages of predicted values (%pred), which
were calculated using the formulas of the Japanese Respira-
tory Society (JRS) adjusted for sex, height, and age [18].
Total lung capacity (TLC), functional reserve capacity
(FRC), and residual volume (RV) were measured using the
helium gas dilution method, and the diffusing capacity of
carbon monoxide (DLco) was measured using the single-
breath-holding method [19]. Predicted values for each lung
volume parameter were estimated using Grimby's formula
[20], and predicted values for DLco were estimated using
Burrows's formula [21].
2.5. Baseline and follow-up data on respiratory function
Baseline respiratory function was estimated from the ﬁrst
measurement, which was conducted at our hospitals in 21
patients and at another hospital in one patient.
To estimate the annual change (Δ) in FVC, TLC, RV/TLC, and
DLco, we used respiratory function data collected over the
period of at least 1 year. The annual change for each patient
was estimated using simple linear regression, assuming time-
dependency and linearity [17]. It was expressed as an absolute
value and as a percentage of change from the baseline value.
The annual change in RV/TLC (%) was deﬁned as the slope on
a linear equation obtained by linear regression.
Because the number of measurements of FVC and the
years of follow-up differed among patients, a mixed-effect
linear regression analysis was performed to estimate the
annual decline of FVC for the whole cohort of patients
(n¼21), using FVC as a dependent variable, and years and
patients (random effect) as independent variables.
The institutional review board of the Fukuoka University
Hospital approved this retrospective study (#15-5-13,
approved on May 27, 2015).
2.6. Statistical analysis
Numerical data are shown as mean7SD. Po.05 indicated statis-
tical signiﬁcance. The correlation between FVC and RV/TLC was
assessed using Pearson's correlation. An extended kappa for the
multi-interpreter agreement [22] for analysis of CT images and
mixed-effect linear regression analysis was performed using SAS
statistical software, version 9.4 (SAS Institute, USA); other analyses
were performed using Prism 5 (GraphPad Software, USA).Exertional dyspnea 8
Dry cough 6
Chest pain 4
Cough and sputum 3
Weight loss 1
Body mass index (kg/m2) 17.172.1a
Crackles: audible/not audible 11/11






The enrolled patients consisted of 13 females and nine males
(Table 1). Fourteen patients have been reported previously
[17,23,24]. We also previously reported nine patients with
IPUF [17]. As the histology of IPUF is the same as that of PPFE,
we included those nine patients in this analysis.Age at onset was ranged from 41 to 81 years (56.6711.0
years). Sixteen patients had never smoked. Steroids were
administered to nine patients, but had no beneﬁcial effect.
Nontuberculous mycobacteria (NTM) were isolated from spu-
tum twice or more in three patients (Mycobacterium avium in
two of these patients). Rheumatoid arthritis (in one patient)
and ulcerative colitis (in one patient) were noted as comor-
bidities. These patients were treated with nonsteroidal anti-
inﬂammatory drugs and mesalazine, respectively. Two
patients had suffered from Hashimoto's disease or Basedow's
disease previously. One patient had worked as a welder for 26
years. One patient had esophageal cancer that had been
irradiated 4 years prior to his death.
Cough or exertional dyspnea was the main symptom in
the patients. Chest pain appeared in four patients. Patients
were slender, with a BMI of 17.172.1 kg/m2. Crackles
were audible in 11 of the 22 patients. Thirteen patients died
1.8–14.8 years after the onset of the ﬁrst symptom. A Kaplan–
Meier survival curve for the 22 patients showed that the
median survival was 7.3 years.
3.2. Histological and imaging ﬁndings
Histological features that are essential for PPFE were found in
all patients; these included intra-alveolar collagenosis and
subpleural elastosis, with preserved alveolar structures, as
reported previously [6,10]. Collagenous thickening of visceral


























ﬁelds by a majority
decision
1 U U U U≒L U U U≒L U≒L U≒L U U≒L 6/5/0 U
2 U≒L U U U≒L U U U U≒L U U U 8/3/0 U
3 U≒L U U U U U U U U≒L U≒L U≒L 7/4/0 U
4 U U U U≒L U U U≒L U≒L U U≒L U 7/4/0 U
5 U≒L U U U≒L U U≒L U U≒L U U≒L U≒L 5/6/0 U≒L
6 U U U U U U U U U U U 11/0/0 U
7
8 U U U U U U U U U U U 11/0/0 U
9 U U U U U U U U U U U 11/0/0 U
10 U≒L U≒L U U≒L U≒L U≒L U≒L U≒L U≒L L U≒L 1/9/1 U≒L
11 U≒L U U U≒L U U U U≒L U≒L U U 7/4/0 U
12 U≒L U≒L U U≒L U≒L U≒L U≒L U≒L U≒L U≒L U≒L 1/10/0 U≒L
13 U≒L U U U U U U≒L U≒L U U≒L U 7/4/0 U
14 U U U U U U U U U U U 11/0/0 U
15 U U U U U≒L U U U U U U 10/1/0 U
16 U U U U U U U U U U U 11/0/0 U
17 U U U U≒L U U U U≒L U U U 9/2/0 U
18 U≒L U≒L U U≒L U≒L U≒L U≒L U≒L U≒L L L 1/8/2 U≒L
19 U U≒L U U≒L U≒L U≒L U U≒L U≒L U U 5/6/0 U≒L
20 U U U U≒L U U U≒L U≒L U U U 8/3/0 U
21 U≒L U≒L U U≒L U≒L U≒L U≒L U≒L U≒L U U≒L 2/9/0 U≒L
22 U U U U U U U U U U U 11/0/0 U
150/78/3 15/6
(total) (U/U≒L)
U: upper lung ﬁeld predominant; U≒L: upper and lower lung ﬁelds equally involved; L: lower lung ﬁeld predominant.
An extended kappa for the multi-interpreter agreement was 0.341 (CI: 0.166–0.503). Since the sample size was not sufﬁciently large to apply the asymptotic theory, the bootstrap resampling method









































Fig. 1 – Chest computed tomography (CT) images presenting upper lung ﬁeld predominance (A, patient #9) and equal
involvement of upper and lower lung ﬁelds (B, #12; C, #18). Two of the 11 interpreters selected CT images of (C) for lower lung
ﬁeld predominance.
Fig. 2 – Relationship between residual volume/total lung
capacity (RV/TLC) and forced vital capacity (FVC). The
baseline values of RV/TLC (%) correlated negatively with
those of FVC (mL).
Table 3 – Baseline values of respiratory function
parameters.
FVC
Number of subjects 22
FVC (mL) 20047735
FVC (% pred) 66.0720.1
Static lung volumes
Number of subjects 19
TLC (mL) 34547943
TLC (% pred) 72.1720.5
RV/TLC (%) 46.4712.9
RV/TLC (% pred) 144.07745.8
DLco
Number of subjects 18
DLco (mL/min/mmHg) 11.473.9
DLco (% pred) 72.5723.5
(mean7SD)
FVC: forced vital capacity; TLC: total lung capacity; RV: residual
volume; DLco: diffusing capacity of carbon monoxide.
r e s p i r a t o r y i n v e s t i g a t i o n 5 4 ( 2 0 1 6 ) 1 6 2 – 1 6 9166pleura was found in 14 of the 22 patients. There was no
disagreement regarding the histological diagnosis of PPFE
among the three reviewers.One-hundred-and-ﬁfty series of CT images were interpreted
as showing upper lung ﬁeld predominance, 78 were interpreted
as showing equal involvement of the upper and lower lung
ﬁelds, and three were interpreted as showing lower lung ﬁeld
predominance (Table 2). Based on a majority decision reached
Table 4 – Changes per year of respiratory function
parameters.
FVC
Number of subjects 21
ΔFVC (mL) 2417203
ΔFVC (% from baseline) 11.279.3
Follow-up period (years) 4.5473.45
Number of measurement per patient 11.177.2
Static Lung Volumes
Number of subjects 14
ΔTLC (mL) 4437355
ΔTLC (% from baseline) 12.479.6
ΔRV/TLC (%) 2.2375.86
Follow-up period (years) 2.7172.37
Number of measurement per patient 7.573.7
DLco
Number of subjects 11
ΔDLco (mL/min/mmHg) 1.4371.58
ΔDLco (% from baseline) 13.5714.1
Follow-up period (years) 1.9670.79
Number of measurement per patient 5.572.3
(mean7SD)
Δ: change per year; FVC: forced vital capacity; TLC: total lung
capacity; RV: residual volume; DLco: diffusing capacity of carbon
monoxide. Change per year for each patient was calculated using a
simple linear regression.
Fig. 3 – Annual change in forced vital capacity (FVC), total
lung capacity (TLC), residual volume/total lung capacity (RV/
TLC), and diffusing capacity of carbon monoxide (DLco). The
values of FVC, TLC, and DLco declined annually; in contrast,
RV/TLC increased. Annual changes were estimated using
simple linear regression. Annual changes in FVC, TLC, and
DLco were expressed as the percentage of change from the
baseline, and the annual change in RV/TLC was deﬁned as
the slope of a linear equation obtained by linear regression.
Fig. 4 – Time-course decline of forced vital capacity (FVC).
The decline of FVC indicated by the thick-line graphs was
gradual during more than 6 years of follow-up. However,
the decline of FVC indicated by the thin-line graphs seemed
more rapid, over a shorter follow-up period. Deceased
patients are denoted by †.
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having ﬁbrotic lesions, with upper lung ﬁeld predominance
(Fig. 1A), and the remaining six patients were considered
as having equal involvement of upper and lower lung
ﬁelds (Fig. 1B and C). The extended kappa for the multi-
interpreter agreement was 0.341 (95% conﬁdence interval [CI]:
0.166–0.503).3.3. Baseline values and yearly decline in respiratory
function parameters
The baseline levels of FVC and DLco were lower than the
predicted values: 20047735mL (66.0720.1%pred) and 11.47
3.9 mL/min/mmHg (72.5723.5%pred), respectively. The baseline
levels of TLC (34547943mL; 72.1720.5%pred) decreased as
observed for FVC and DLco, but those of RV/TLC increased
(144.0745.8%pred; Table 3). Initial FVC (mL) correlated nega-
tively with RV/TLC (%) (r¼0.517, P¼0.023; Fig. 2).
ΔFVC was 2417203mL (11.279.3%). TLC and DLco also
declined annually: 4437355mL (12.479.6%) and 1.4371.58
mLmin–1 mmHg–1 (13.5714.1%), respectively. In contrast, ΔRV/
TLC was increased (2.2375.86%; Table 4 and Fig. 3).
Fig. 4 shows the time-course changes in FVC in the
patients (n¼21). A mixed-effect regression analysis of the
whole cohort of patients ﬁt well with an FVC decline of
135 mL/year and an R2 of 0.679. The patients seemed to be
divided into two groups according to the different patterns of
FVC decline: one showed a gradual decline in FVC over a
follow-up period of more than 6 years in ﬁve patients, while
the other showed a relatively rapid decline in FVC over a
shorter follow-up period. When the two groups were ana-
lyzed separately, the annual decline and R2 were 55 mL/
year and 0.799, and 364 mL/year and 0.855, respectively.4. Discussion
Currently, PPFE is known to have a well-established histolo-
gical pattern; its histology is quite characteristic and is
distinct from that of UIP and other IIPs. In contrast, its clinical
features in relation to other chronic ﬁbrosing IIPs, in parti-
cular idiopathic pulmonary ﬁbrosis (IPF), have not been fully
elucidated. This study aimed to identify the imaging and
functional characteristics of patients with pulmonary ﬁbrosis
r e s p i r a t o r y i n v e s t i g a t i o n 5 4 ( 2 0 1 6 ) 1 6 2 – 1 6 9168presenting a PPFE histology, regardless of the presence or
absence of associated diseases or underlying conditions.
Various underlying conditions or diseases have been reported
in PPFE; however, it is not clear whether they are closely related
to the occurrence and development of PPFE or whether they are
simply comorbidities that incidentally complicate the condition.
The reported number of patients with PPFE is limited. We
investigated the signiﬁcant features of PPFE in terms of patho-
genesis and pathophysiology, by taking all clinical backgrounds
and underlying conditions into consideration.
Four patients had a current or past autoimmune disease
as a comorbidity; autoimmune predisposition may be partly
responsible for the pathogenesis of PPFE [10]. NTM were
repeatedly isolated from sputum in three patients. Rifampi-
cin, ethambutol, and clarithromycin were administered to
two patients, albeit without a favorable effect. However, NTM
infection may be pathognomonic to PPFE, rather than simply
being a comorbidity. In one patient, Mycobacterium avium was
isolated from sputum during the early stages of PPFE, and the
infection progressed along with the progression of PPFE. A
mixed-effect linear regression analysis was performed after
excluding two patients in whom PPFE was probably not
idiopathic, but rather secondary (patient #6, who had active
rheumatoid arthritis, and patient #21, who had been irra-
diated for esophageal cancer); the results of this analysis was
virtually the same as those obtained for analysis of the 21
patients. The annual decline in the 19 patients was 132 mL/
year, with an R2 of 0.679. The annual decline in the subgroup
of rapid decliners was 365 mL/year, with an R2 of 0.858, and
that in the subgroup of gradual decliners was the same as the
previous result, because the two patients who had been
excluded were both rapid decliners. The extended kappa for
the level of agreement among the 11 interpreters after
excluding the two patients was 0.302 (95% CI: 0.137–0.485).
Although the ofﬁcial statement by the ATS/ERS [1] empha-
sizes the predominant involvement of the upper lung lobes in
PPFE, our results showed that, although in some cases, the
upper lung ﬁeld was predominantly involved, in other cases,
the upper and lower lung ﬁelds were equally involved. Amitani
disease, which exclusively involves ﬁbroelastosis in the upper
lobes [2], may be one end of a wide spectrum of pulmonary
ﬁbrosis showing PPFE histology. It is possible that PPFE is not as
rare as was thought previously [25]. In addition, we showed that
a considerable number of patients have pulmonary ﬁbrosis
with PPFE histology, without upper lung ﬁeld predominance.
The concept of upper lung ﬁeld predominance may be the
result of biased biopsies. The chance of undergoing biopsy
may be higher in patients who have upper lobe ﬁbrosis on CT
images, under a suspected diagnosis of PPFE or non-UIP
lacking lower lobe-dominant ﬁbrosis. However, 11 inter-
preters, 10 of whom had more than 10 years of experience
in the ﬁeld of pulmonology, concluded from the CT images
that the upper and lower lung ﬁelds were equally involved in
about one-third of the CT image series in our patients. The
biopsied samples obtained from patients whose clinical
diagnosis does not appear to be PPFE should be reviewed to
examine whether ﬁbroelastosis is truly rare among IIPs.
Increased RV/TLC, which is not typically observed in IPF, is
quite characteristic of PPFE, and our results were similar to
those reported by other investigators [11,26,27]. We furtherdemonstrated that RV/TLC was inversely correlated with FVC,
i.e., an increase in RV/TLC may appear in the advanced stage of
PPFE. This relationship between initial RV/TLC and FVC is
consistent with the subsequent changes seen in these para-
meters in a time-course: FVC and TLC decreased over time,
whereas RV/TLC increased, although marginally. Fibrotic col-
lapse of the upper lobes may lead to compensatory overinﬂa-
tion of the lower lobes, probably resulting in increased RV/TLC
[28]. Another possibility is that the ﬂattened chest cage
observed in the advanced stage of PPFE [24] may restrict the
expansion of both lungs. Restricted mobility in relatively well-
preserved lower lobes may be responsible for the increased RV/
TLC observed; alternatively, a decrease in the strength of the
respiratory muscles may be responsible for this phenomenon.
As reported previously, FVC declined over time in most
patients; however, in the present study, the annual decline in
FVC followed two patterns: a rapid decline in FVC over a short
period, as has been demonstrated previously [17], and a slow
decline in FVC over a longer period. These patterns suggest that
the clinical course of PPFE is heterogeneous; or that the decline in
FVC may not be linear. We postulate that FVC declines gradually
to a point in time, after which it begins to decline rapidly. We
may only have observed the gradually declining FVC phase in ﬁve
patients, and the rapidly declining phase in the 16 patients who
had already passed the endpoint of the gradually declining phase.
The present study had several limitations. Our study was a
retrospective study. In most of the patients who had under-
gone lung biopsy, samples were obtained from the upper
lobes. The biopsied specimens in patients with lower lung
ﬁeld-predominant ﬁbrosis should be reviewed after staining
for elastic ﬁbers to detect ﬁbroelastosis.
Not all of the CT images were interpreted without clinical
information: YY and KW interpreted CT images after review-
ing the clinical information of all patients, and each inter-
preter recognized his or her patients' CT images as the
respective attending physician. Although the kappa value
did not seem to be sufﬁciently large, disagreement was
unavoidable when abnormal opacities were diffusely distrib-
uted. Therefore, we used a majority decision to determine the
predominantly involved sites from among three alternatives.
Fibrosis of PPFE extends to the lower lung ﬁelds as the
disease progresses. Our analysis of CT images may be biased
due to inclusion of cases with advanced PPFE. However, the
FVC %pred obtained in our study (66.0720.1) was not markedly
low as compared with the FVC or VC %pred values reported by
other investigators: 59.2726.5 [2], 60.7716.6 [3], 50.0715.8 [6],
73.9712.2 [11], and 70.5 [25], 76.5 [26], and 56.9715.6 [27].
We obtained a high R2 in the mixed-effect linear regres-
sion analysis of the entire group of patients. However, the
annual decline estimated by mixed-effect linear regression
(135 mL) was considerably different from that obtained by
simple linear regression (2417203 mL; Table 4). This may
be partly because the absolute value of FVC was different in
each patient and because the number of patients was small.5. Conclusions
We have demonstrated that the mainly involved sites as
determined by CT images were not limited to the upper lobes
r e s p i r a t o r y i n v e s t i g a t i o n 5 4 ( 2 0 1 6 ) 1 6 2 – 1 6 9 169in patients with pulmonary ﬁbrosis and PPFE histology. In one-
third of the CT image series of the patients in this study, the
upper and lower lung ﬁelds were equally involved. There
appears to be two patterns of FVC decline: a rapid decline over
a short period and a slow decline over a longer period, suggest-
ing that the disease follows a heterogeneous clinical course.Conﬂict of interest
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